Sight Sciences, Inc. (SGHT)

Market Cap	181.19M
Revenue (ttm)	79.54M
Net Income (ttm)	-50.35M
Shares Out	50.75M
EPS (ttm)	-1.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	458,254
Open	3.350
Previous Close	3.360
Day's Range	3.300 - 3.640
52-Week Range	3.160 - 8.450
Beta	2.57
Analysts	Buy
Price Target	6.27 (+75.63%)
Earnings Date	Nov 7, 2024

About SGHT

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company’s products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trab...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 15, 2021
• Employees: 214
• Stock Exchange: NASDAQ
• Ticker Symbol: SGHT
• Website: https://www.sightsciences.com

Financial Performance

In 2023, Sight Sciences's revenue was $81.06 million, an increase of 13.63% compared to the previous year's $71.33 million. Losses were -$55.55 million, -35.59% less than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for SGHT stock is "Buy." The 12-month stock price forecast is $6.27, which is an increase of 75.63% from the latest price.

Price Target

$6.27

(75.63% upside)

Analyst Consensus: Buy